A major inhibitor of phenytoin binding to serum protein in uremia.
A major endogenous ligand substance, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), accumulated in the sera of uremic patients, inhibited phenytoin binding to pooled serum obtained from healthy subjects and to human serum albumin in a concentration usually observed in the sera of patients with uremia. This suggests that CMPF is a major drug-binding inhibitor present in uremic serum and may be one of the so-called 'uremic toxins'.
Mabuchi
H
H
Department of Internal Medicine and Nephrology, Nishijin Hospital, Kyoto, Japan.
Nakahashi
H
H
D000328:Adult; D001667:Binding, Competitive; D005663:Furans; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000097:blood*; D011422:Propionates / Q000097:blood*; D011485:Protein Binding / Q000187:drug effects; D012709:Serum Albumin / Q000378:metabolism*; D014511:Uremia / Q000097:blood*
D005663:Furans; D011422:Propionates; D012709:Serum Albumin; D010672:Phenytoin; C041693:3-carboxy-4-methyl-5-propyl-2-furanpropionic acid